Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
- PMID: 30275265
- PMCID: PMC6214765
- DOI: 10.3899/jrheum.171362
Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
Abstract
Objective: Forced vital capacity (FVC) and DLCO are used for screening of systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study purpose was to determine the sensitivity, specificity, and negative predictive value (NPV) (proportion of true negative screening tests) of FVC and DLCO thresholds for SSc-ILD on chest high-resolution computed tomography (HRCT) scans.
Methods: Patients fulfilling American College of Rheumatology 2013 SSc criteria with a chest HRCT scan and pulmonary function tests (PFT) were studied. A thoracic radiologist quantified radiographic ILD. Optimal FVC and DLCO % predicted thresholds for ILD were identified using receiver-operating characteristic curves. The FVC and DLCO combinations with greatest sensitivity and specificity were also determined. Subanalysis was performed in patients with positive Scl-70 autoantibodies.
Results: The study included 265 patients. Of 188 (71%) with radiographic ILD, 59 (31%) had "normal" FVC (≥ 80% predicted), and 65 out of 151 (43%) had "normal" DLCO (≥ 60% predicted). FVC < 80% (sensitivity 0.69, specificity 0.73), and DLCO < 62% (sensitivity 0.60, specificity 0.70) were optimal thresholds for radiographic SSc-ILD. All FVC and DLCO threshold combinations evaluated had NPV < 0.70. The NPV for radiographic ILD for FVC < 80% was lower in patients with positive Scl-70 autoantibody (NPV = 0.05) compared to negative Scl-70 autoantibody (NPV = 0.57).
Conclusion: Radiographic ILD is prevalent in SSc despite "normal" PFT. No % predicted FVC or DLCO threshold combinations yielded high NPV for SSc-ILD screening. "Normal" FVC and DLCO in patients with SSc, especially those with positive Scl-70 autoantibodies, should not obviate consideration of HRCT for ILD evaluation.
Keywords: FORCED VITAL CAPACITY; INTERSTITIAL LUNG DISEASE; SYSTEMIC SCLEROSIS.
Figures

Similar articles
-
KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).Semin Arthritis Rheum. 2024 Apr;65:152366. doi: 10.1016/j.semarthrit.2024.152366. Epub 2024 Jan 13. Semin Arthritis Rheum. 2024. PMID: 38290372
-
Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.Arthritis Rheumatol. 2015 Dec;67(12):3256-61. doi: 10.1002/art.39405. Arthritis Rheumatol. 2015. PMID: 26316389
-
Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.Semin Arthritis Rheum. 2017 Oct;47(2):228-234. doi: 10.1016/j.semarthrit.2017.03.019. Epub 2017 Apr 1. Semin Arthritis Rheum. 2017. PMID: 28454677
-
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.Eur Respir Rev. 2018 May 15;27(148):170102. doi: 10.1183/16000617.0102-2017. Print 2018 Jun 30. Eur Respir Rev. 2018. PMID: 29769294 Free PMC article.
-
Predictors of progression in systemic sclerosis patients with interstitial lung disease.Eur Respir J. 2020 May 14;55(5):1902026. doi: 10.1183/13993003.02026-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32079645 Free PMC article. Review.
Cited by
-
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort.Rheumatology (Oxford). 2023 Jul 5;62(7):2501-2509. doi: 10.1093/rheumatology/keac639. Rheumatology (Oxford). 2023. PMID: 36377780 Free PMC article.
-
Detection and classification of systemic sclerosis-related interstitial lung disease: a review.Curr Opin Rheumatol. 2019 Nov;31(6):553-560. doi: 10.1097/BOR.0000000000000660. Curr Opin Rheumatol. 2019. PMID: 31415029 Free PMC article. Review.
-
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.Am J Respir Crit Care Med. 2025 Jul;211(7):1132-1155. doi: 10.1164/rccm.202505-1054ST. Am J Respir Crit Care Med. 2025. PMID: 40387336 Free PMC article. Review.
-
Regulator combinations identify systemic sclerosis patients with more severe disease.JCI Insight. 2020 Sep 3;5(17):e137567. doi: 10.1172/jci.insight.137567. JCI Insight. 2020. PMID: 32721949 Free PMC article.
-
The Value of Ultrasound for Detecting and Following Subclinical Interstitial Lung Disease in Systemic Sclerosis.Tomography. 2024 Apr 3;10(4):521-532. doi: 10.3390/tomography10040041. Tomography. 2024. PMID: 38668398 Free PMC article.
References
-
- Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med. 2014;43:329–343. - PubMed
-
- Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheum. 2015;67:3256–3261. - PubMed
-
- Steele R, Hudson M, Lo E, Baron M, Canadian Scleroderma Research G Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res. 2012;64:519–524. - PubMed
-
- Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–1254. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous